These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3593896)

  • 1. Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution.
    Wright GJ; Melikian AP; Pitts JE; Crowe JT; Morley EM
    Biopharm Drug Dispos; 1987; 8(2):159-72. PubMed ID: 3593896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sustained-release quinidines given twice daily to patients with ventricular ectopy.
    Lehmann CR; Boran KJ; Kruyer WB; Van Reet RE; Scoville GS; Pierson WP; Melikian AP; Crowe JT; Wright GJ
    J Clin Pharmacol; 1986; 26(8):598-604. PubMed ID: 3793950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
    Covinsky JO; Russo J; Kelly KL; Cashman J; Amick EN; Mason WD
    J Clin Pharmacol; 1979; 19(5-6):261-9. PubMed ID: 469022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.
    Bottorff MB; Lalonde RL; Straughn AB
    Biopharm Drug Dispos; 1987; 8(3):213-21. PubMed ID: 3297181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of three commercial quinidine dosage forms.
    Sirois G; Eshaque M; Chabot M
    Biopharm Drug Dispos; 1980; 1(4):167-77. PubMed ID: 7448345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Average steady-state plasma levels with slow release quinidine preparations].
    Normand JP; Roux A; Bardet J; Kahn JC; Maspoli JJ; Jarreau FX; Sansarricq M; Flouvat B; Bourdarias JP
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1006-13. PubMed ID: 116611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans.
    McGilveray IJ; Midha KK; Rowe M; Beaudoin N; Charette C
    J Pharm Sci; 1981 May; 70(5):524-9. PubMed ID: 7241357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol.
    Powell ML; Weisberger M; Dowdy Y; Gural R; Symchowicz S; Patrick JE
    Biopharm Drug Dispos; 1987; 8(5):461-8. PubMed ID: 3663882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability study of three sustained release quinidine formulations.
    Mahon WA; Leeder JS; Brill-Edwards MM; Correia J; MacLeod SM
    Clin Pharmacokinet; 1987 Aug; 13(2):118-24. PubMed ID: 3621768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.
    Leeuwenkamp OR; Visscher HW; Mensink CK; Jonkman JH
    Eur J Clin Pharmacol; 1994; 46(3):243-7. PubMed ID: 8070505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.